Examining the Validity of External Controls Relative to Randomized Controls
This presentation discusses the validity of external controls in medical product development and their comparison to randomized controls.
- Publisher
- European Medicines Agency (EMA)
- Length
- 19 pages
- File
- 5.0 MB PDF
Quick answer
Examining the Validity of External Controls Relative to Randomized Controls is a 19-page whitepaper from European Medicines Agency (EMA) covering EU pharma intelligence. This presentation discusses the validity of external controls in medical product development and their comparison to randomized controls.
Research library Data sources More from European Medicines Agency (EMA)
Why this matters
This presentation discusses the validity of external controls in medical product development and their comparison to randomized controls.
Executive summary
- This presentation discusses the validity of external controls in medical product development and their comparison to randomized controls.
Market Impact
| Regulatory | high |
|---|---|
| Commercial | high |
| Competitive | medium |
| Investment | high |
Who should read this
- EU market access specialists
Ask about this report
AI-assisted answers grounded in NovaPharmaNews intelligence
Answers use retrieved site intelligence plus AI synthesis. Verify critical decisions with primary sources.
Download the full 19-page PDF
Free · 5.0 MB · Instant access after email
Frequently asked questions
What whitepapers does NovaPharmaNews publish?
Our research library curates FDA, EMA, and industry publisher PDFs — regulatory guidance, clinical analyses, manufacturing reports, and market intelligence. Each report includes an AI-summarized landing page with key takeaways and a gated PDF download.
How do I download a whitepaper?
Open any report page, scroll to the download form, and enter your work email. You receive instant PDF access and can opt in to weekly pharma intelligence updates. Downloads are free for healthcare professionals.
How do whitepapers connect to news and pipeline data?
Report pages link to related intelligence — company profiles, drug INN pages, clinical trials, pipeline programs, and topic hubs. Use the intelligence spokes on each page to explore the entity graph behind the research.
Ready to read the full report?
Join 12,000+ pharma leaders getting deep industry analysis delivered weekly.
Related topic hubs
Editorial coverage and intelligence directories for this report's beat.
Explore the intelligence platform
Related intelligence
🔒 EFPIA Patients W.A.I.T. Indicator 2025: Europe access trends, reimbursement and time-to-availability
Full availability on public reimbursement lists stands at 28%, down from 29% in the 2024 study, indicating a declining trend in unrestricted…
🔒 EMA 2025 Annual Report Annexes: Committees, Opinions, and Governance
The document comprises 24 annexes documenting EMA committee memberships, 2025 scientific opinions, and regulatory decisions across human and…
🔒 Healthcare investment in Central and Eastern Europe: what pharma teams should know
CEE governments invested an average of 5.47% of GDP in healthcare in 2023, compared with 8.17% in the EU4 (Germany, France, Italy, Spain). T…